Abstract:Purpose An oil/water nanoemulsion was developed in the present study to enhance the solubility, stability and anti-tumor activity of a novel 10-methoxy-9-nitrocamptothecin (MONCPT). Materials and Methods MONCPT nanoemulsion was prepared using Lipoid E80 and cremophor EL as main emulsifiers by microfluidization. The droplet size of the nanoemulsion was measured by dynamic light scattering. In vitro drug release was monitored by membrane dialysis. Kinetics of MONCPT transformed into carboxylic salt was performed in phosphate buffer at different pH. Hemolysis of MONCPT nanoemulsion was conducted in rabbit erythrocytes. Solubilization character of MONCPT in nanoemulsion was experimented using Nile red as a solvatochromic probe. In vitro cytotoxicity of the nanoemulsion was measured in A549 and S180 cells using Sulforhodamine B protein stain method, and suppression rate of tumor growth was investigated in S180-bearing mice. The cell cycle effects of MONCPT nanoemulsion on S180 cells were analyzed by flow cytometry. Distribution of the nanoemulsion in A549 cells and S180-bearing mice were also investigated by fluorescence image. Results MONCPT is incorporated in the nanoemulsion in form of lactone with concentration of 489 µg/ml, more than 200 folds higher than that in water. Experiments using Nile red as a solvatochromic probe indicated that more MONCPT might be located in the interfacial surfactant layer of the nanoemulsion than that in discrete oil droplet or continuous aqueous phase. Nanoemulsion could release MONCPT in a sustained way, and it was further shown to notably postpone the hydrolysis of MONCPT with longer hydrolysis half-life time (11.38 h) in nanoemulsion at pH 7.4 than that of MONCPT solution (4.03 h). No obvious hemolysis was caused by MOCPT nanoemulsion in rabbit erythrocytes. MONCPT nanoemulsion showed a marked increase in cytotoxic activity, 23.6 folds and 28.6 folds in S180 cells and A549 cells respectively via arresting the cell at G2 phase, compared to that induced by MONCPT injection. It correlated well to the in vivo anti-tumor activity of MONCPT nanoemulsion with suppression rate of 93.6%, while that of MONCPT injection was only 24.2% at the same dosage. Moreover, nanoemulsion exhibited enhanced capability of delivering drug into malignant cell’s nucleus in vitro and induced drug accumulation in tumor in S180-bearing mice using in vivo imaging. Conclusion The nanoemulsion prepared exhibited an improved MONCPT solubility, stability and anti-tumor activity, providing a promising carrier for cancer chemotherapy using MONCPT.

Effect of Tween80 on the Pharmacokinetics of 9-nitrocamptothecin Liposome

Pharmacokinetics and Tissue Distribution in Tumor-bearing Mice After iv Administration of 9-Nitrocamptothecin with Different Lactone Ratios

[9-Nitrocamptothecin Nanostructured Lipid Carrier System: in Vitro Releasing Characteristics, Uptake by Cells, and Tissue Distribution in Vivo].

Preparation of 9-Nitrocamptothecin Liposome and Its Pharmacokinetic after Pulmonary Delivery to Rats

Biodistribution in Mice and Severity of Damage in Rat Lungs Following Pulmonary Delivery of 9-Nitrocamptothecin Liposomes

Pharmacokinetics and Urinary Excretion of 9-Nitrocamptothecin Following Intravenous Administration of Lactone and Carboxylate Forms to Rats

Protection Effect of Self-Emulsifying Microemulsion on 9-Nitrocamptothecin Lactone Form

Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.

Effect of a 2-HP-β-Cyclodextrin Formulation on the Biological Transport and Delivery of Chemotherapeutic PLGA Nanoparticles

Complex of 9-nitro-camptothecin in hydroxypropyl-β-cyclodextrin: In vitro and in vivo evaluation

Effects of Borneol on the Pharmacokinetics of 9-Nitrocamptothecin Encapsulated in PLGA Nanoparticles with Different Size Via Oral Administration

Enhanced Oral Bioavailability of Docetaxel by Lecithin Nanoparticles: Preparation, in Vitro, and in Vivo Evaluation

Effects of Modification of Transferrin on Cytotoxicity and Intracellular Delivery of Paclitaxel Loaded PLGA Nanoparticles

A Novel Camptothecin Derivative Incorporated in Nano-Carrier Induced Distinguished Improvement in Solubility, Stability and Anti-tumor Activity Both In Vitro and In Vivo

Effects of liposomal paclitaxel and paclitaxel in treatment of non-small-cell lung cancer(64 patients) and breast cancer(62 patients)

Characterization and pharmacodynamic evaluation in vitro of 9-nitro-camptothecin-loaded folate-conjugated polymer micelles as tumor-targeted drug delivery system

Effect of Cationic Liposome Formulation on Human Carcinoma Hepatic SMMC-7721 Cells' Uptake of Tenofovir and Cytotoxicity

Study on the Protection of Self-Emulsification Microemulsion Tolactone Structure of 9-Nitrocamptothecin

[The in Vitro Kinetics of Uptake, Transport and Efflux of 9-Nitrocamptothecin in Caco-2 Cell Model].

Nanocarrier Improves the Bioavailability, Stability and Antitumor Activity of Camptothecin

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo